Cambridge, UK; 24th May 2021

Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a rare disease specialist pharmaceutical company acquiring, developing and commercializing therapeutics that address unmet patient needs, specializing in gastroenterology, attended virtual Digestive Disease Week® (DDW) between 21st to 23rd May 2021.

There were over 2000 expert sessions describing the latest research and thinking around the care of patients with gastrointestinal diseases. It was exciting to note that Inflammatory Bowel Disease continued to dominate the conference agenda, a reflection of patient needs, physician interest and ongoing research.

Clinical data were presented for a number of therapies for patients with moderate to severe ulcerative colitis and Crohn’s disease. These data focused on treatment efficacy, safety and ease of administration which remain key concerns for patients and their physicians. The clinical presentations signposted additional therapeutic options for patients and highlighted clinical and translational research in the field that would allow for improved patient selection and treatment optimisation.

Atlantic Healthcare observed that its product alicaforsen, remains well positioned to become a novel therapeutic treatment class for patients with active moderate to severe ulcerative colitis and Crohn’s disease. Furthermore, Atlantic Healthcare’s clinical development plans for enema and oral formulations of alicaforsen are in keeping with the latest advances in the field.

~ ENDS ~

About Atlantic Healthcare

Atlantic Healthcare plc (https://www.atlantichc.com) is a rare disease specialist pharmaceutical company acquiring, developing and commercializing therapeutics that address unmet patient needs, specializing in gastroenterology.

The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug, in development for ulcerative colitis and Crohn’s disease. It also owns renzapride, a novel therapy, which has the potential to address the unmet needs of multiple patient groups suffering gastrointestinal motility disorders associated with cystic fibrosis, systemic scleroderma and Parkinson’s disease.

Forward Looking Statements

While Atlantic Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Atlantic Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Atlantic Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.